EGFR inhibitor
EGFR tyrosine kinase inhibitor
- Suppresses EGFR-mutant lung cancer and other EGFR-dependent tumors
- Normal epithelial blockade → acneiform rash and diarrhea
- Rash can track response
- Targets EGFR-mutant non-small cell lung cancer
- Acneiform rash and diarrhea are class effects
Drugs with this mechanism (6)
- Afatinib — Irreversible EGFR inhibitor for selected EGFR-mutant lung cancer; diarrhea and rash limit use.
- Dacomitinib — Irreversible EGFR-family inhibitor for EGFR-mutated lung cancer; diarrhea, rash, and stomatitis commonly limit treatment.
- Erlotinib — EGFR inhibitor for lung and pancreatic cancer; gastric acid is needed for absorption.
- Gefitinib — EGFR tyrosine kinase inhibitor for EGFR-mutated lung cancer; rash, diarrhea, and rare interstitial lung disease.
- Lapatinib — Oral HER2/EGFR inhibitor used in combination for HER2-positive breast cancer; diarrhea, hepatotoxicity, and cardiac dysfunction.
- Osimertinib — Third-generation EGFR inhibitor for lung cancer with the T790M mutation.
All mechanisms · Open EGFR inhibitor in the interactive console ↗